← Back to overview

KVUE Kenvue Inc.

Personal Care Products · $19.28 +2.01%
Price Alert:
Price & Volume
RSI (14)
MACD (12, 26, 9)

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
69.9
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
19.17 / 19.01 / —
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
0.06 / 0.06
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
23.0
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
37.02B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
4.30%
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
14.02 – 22.74
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Kenvue Inc. is trading at $19.28, +2.01% versus the previous close. The price sits roughly in the middle of its 52-week range.
RSI is in a neutral range — no strong overbought/oversold signal.
MACD is above its signal line — momentum currently leans positive.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)
Simply Wall St. · 2026-07-26 01:09
Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?
Simply Wall St. · 2026-07-26 00:16
Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight
Simply Wall St. · 2026-07-25 15:15
Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse
Insider Monkey · 2026-07-25 12:22
KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback
Stocktwits · 2026-07-24 20:42
Kenvue's Tylenol With Naproxen Combination Tablet Gets FDA Approval for Pain Relief
MT Newswires · 2026-07-24 14:57
Kenvue to Announce Second Quarter 2026 Results on August 6, 2026
Business Wire · 2026-07-23 10:45
Barclays Adjusts Price Target on Kenvue to $19 From $18, Maintains Equalweight Rating
MT Newswires · 2026-07-21 11:05
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.